TP53 and neoplasm: A recent study by Labidi-Galy et al. (2017) showed shared TP53 mutations in patient-matched pre-cancerous and cancerous lesions (including so-called p53 signatures, Serous Tubal Intraepithelial Carcinoma (STIC) lesions and invasive carcinomas) from nine patients with HGSOC, providing support for the possibility of discovering tumour-driving mutations in early stages of the disease11.